Chronic kidney diseases are a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. Now, a monoclonal antibody, named BION-1301 (anti-APRIL), is being developed to treat patients with IgA nephropathy.
BION-1301 is a potential disease-modifying approach to prevent the formation of immune complexes that deposit in the glomeruli of the kidney, causing damage. BION-1301 was developed in a TIP Pharma consortium by prof. Jan Paul Medema and dr. Hans van Eenennaam partly at the Amsterdam UMC and is now a pipeline product of Chinook Therapeutics, which recently reported that during the phase 1 trial, healthy volunteers well-tolerated BION-1301 with no serious adverse events, a pharmacokinetic half-life of approximately 33 days. The antibody demonstrated dose-dependent pharmacodynamic effects characterized by durable reductions in serum levels of free APRIL, IgA, galactose-deficient IgA (Gd-IgA1) and IgM, with a lesser reduction in IgG. Now, BION-1301 is evaluated in patients with IgA nephropathy in a phase 1b trial.
Chinook Therapeutics
Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.
World Congress of Nephrology 2021
The ongoing phase 1 multi-center trial was presented at World Congress of Nephrology 2021.
For more information see WCN21-0706: A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Safety and Bioavailability Study of BION-1301 Administered by Intravenous (IV) and Subcutaneous (SC) Routes.
Imran Avci, from the Department of Physics and Astronomy at Vrije Universiteit Amsterdam, has secured the NOW Demonstrator grant for a project titled SOHO: A New Approach for Ultra-Precise, Fast, and Sensitive Photonic Microchip Measurements. The innovation in this field is expected to lead to breakthroughs in quantum computing, neuromorphic processors, wearable sensors, Lidar systems, […]
NewsLongform.ai BV, a spin-off from the University of Amsterdam (UvA) and based in Amsterdam, has secured €300,000 in funding from Innovatiefonds Noord-Holland. In addition, the company has benefited from extensive mentorship provided by the TTT-AI program, accelerating both its research and commercialization efforts. Longform.ai is building a cutting-edge platform that leverages generative AI to extract […]
NewsWe’re thrilled to share the success of the HvA-wide EXPLORE Workshops, organized by the Venture Centre HvA (part of IXA-HvA). These workshops are designed to ignite entrepreneurial spirit among students, helping them discover their competencies and attitudes. The goal? Equip students to spot opportunities and create value within their fields—whether in business, healthcare, or other […]
News